Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PTC299 for Treatment of Advanced Cancer
NCT00704821 · PTC Therapeutics · PHASE1 · terminated · last registry update 2019-05-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, PTC Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DHODH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-05-07Phase 3 first posted: Immunic AG, IMU-838 (NCT04379271)
- 2020-04-08Phase 3 first posted: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338022)
- 2020-04-08Phase 3 first posted: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338061)
- 2020-04-03Also stopped (terminated): Derrick Scott Robertson, teriflunomide + Colestipol (NCT02263547)
- 2019-07-01Results posted on the registry: Derrick Scott Robertson, teriflunomide + Colestipol (NCT02263547)
- 2019-04-12Also stopped (terminated): PTC Therapeutics, PTC299 (NCT00911248)
- 2018-06-06Also stopped (terminated): AIDS Malignancy Consortium, VEGF inhibitor PTC299 + gene expression analysis (NCT00686842)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision